id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-D-1096-0001,FDA,FDA-2021-D-1096,"Chronic Rhinosinusitis With Nasal
Polyps: Developing Drugs for
Treatment; Draft Guidance for
Industry; Availability",Notice,Notice of Availability,2021-12-10T05:00:00Z,2021,12,2021-12-10T05:00:00Z,2022-02-09T04:59:59Z,2022-02-09T02:00:44Z,2021-26733,0,0,0900006484eb80f8
FDA-2021-D-1096-0002,FDA,FDA-2021-D-1096,Chronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatment Guidance for Industry DRAFT GUIDANCE,Other,Guidance,2021-12-10T05:00:00Z,2021,12,2021-12-10T05:00:00Z,,2023-06-30T14:48:35Z,,0,0,0900006484eb8f7e